1. Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer
- Author
-
César Paz-y-Miño, Néstor W. Soria, Jennyfer M. García-Cárdenas, Andrés López-Cortés, Patricia Guevara-Ramírez, Santiago Guerrero, Gabriela Jaramillo-Koupermann, Isaac Armendáriz-Castillo, Dámaris P. Intriago-Baldeón, Luis A. Quiñones, Paola E. Leone, Ángela León Cáceres, and Juan P Cayún
- Subjects
0301 basic medicine ,Colorectal cancer ,Antineoplastic Agents ,Single-nucleotide polymorphism ,Bioinformatics ,030226 pharmacology & pharmacy ,Causes of cancer ,03 medical and health sciences ,0302 clinical medicine ,Gene Frequency ,Biomarkers, Tumor ,Genetics ,medicine ,Humans ,Gene Regulatory Networks ,Allele frequency ,Therapeutic strategy ,Pharmacology ,business.industry ,medicine.disease ,Precision medicine ,Pharmacogenomics Biomarker ,030104 developmental biology ,Pharmacogenetics ,Pharmacogenomics ,Molecular Medicine ,Colorectal Neoplasms ,business - Abstract
Colorectal cancer is one of the leading causes of cancer death worldwide. Over the last decades, several studies have shown that tumor-related genomic alterations predict tumor prognosis, drug response, and toxicity. These observations have led to the development of several therapies based on individual genomic profiles. As part of these approaches, pharmacogenomics analyses genomic alterations which may predict an efficient therapeutic response. Studying these mutations as biomarkers for predicting drug response is of a great interest to improve precision medicine. We conduct a comprehensive review of the main pharmacogenomics biomarkers and genomic alterations affecting enzyme activity, transporter capacity, channels, and receptors; and therefore the new advances in CRC precision medicine to select the best therapeutic strategy in populations worldwide, with a focus on Latin America.
- Published
- 2019